The head of Forest Laboratories, Howard Solomon, is reportedly slated to make $100 million or more from his company’s $25 billion merger with pharmaceutical giant Actavis, according to reports.
Reports say documents recently filed with the US Securities and Exchange Commission suggest Actavis is preparing to acquire Forest, a notice that hints at corporate restructuring at the firm.
According to reports, Solomon stands to reap major profits from the deal before he is set to leave his position as chairman after the company’s annual meeting later this year.
Full content: Fierce Pharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ABC Technologies Offers to Acquire TI Fluid for £1.83 Billion
Dec 1, 2024 by
CPI
Concerns Mount as Mexico Moves Forward with Telecom Regulator Overhaul
Dec 1, 2024 by
CPI
States Challenge ‘Green Agenda’: Major Asset Managers Accused of Antitrust Breach
Dec 1, 2024 by
CPI
Google Seeks Reversal of Antitrust Ruling in Epic Games Case
Dec 1, 2024 by
CPI
Meta Accused of EU Data Violations in €551 Million Spanish Lawsuit
Dec 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI
Assessing the Potential for Antitrust Moats and Trenches in the Generative AI Industry
Nov 29, 2024 by
Allison Holt, Sushrut Jain & Ashley Zhou
How SEP Hold-up Can Lead to Entrenchment
Nov 29, 2024 by
Jay Jurata, Elena Kamenir & Christie Boyden
The Role of Moats in Unlocking Economic Growth
Nov 29, 2024 by
CPI
Overcoming Moats and Entrenchment: Disruptive Innovation in Generative AI May Be More Successful than Regulation
Nov 29, 2024 by
Simon Chisholm & Charlie Whitehead